CN114470096A - 一种缓解术后白细胞升高的中药配方及其制备工艺 - Google Patents
一种缓解术后白细胞升高的中药配方及其制备工艺 Download PDFInfo
- Publication number
- CN114470096A CN114470096A CN202210146859.8A CN202210146859A CN114470096A CN 114470096 A CN114470096 A CN 114470096A CN 202210146859 A CN202210146859 A CN 202210146859A CN 114470096 A CN114470096 A CN 114470096A
- Authority
- CN
- China
- Prior art keywords
- decoction
- relieving
- wetting agent
- postoperative
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002980 postoperative effect Effects 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000000080 wetting agent Substances 0.000 claims abstract description 24
- 239000002562 thickening agent Substances 0.000 claims abstract description 20
- 241000208340 Araliaceae Species 0.000 claims abstract description 19
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 19
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 19
- 235000008434 ginseng Nutrition 0.000 claims abstract description 19
- 239000000230 xanthan gum Substances 0.000 claims abstract description 17
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 17
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 17
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 17
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims abstract description 16
- 229920001353 Dextrin Polymers 0.000 claims abstract description 8
- 239000004375 Dextrin Substances 0.000 claims abstract description 8
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims abstract description 8
- LWZFANDGMFTDAV-WYDSMHRWSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-WYDSMHRWSA-N 0.000 claims abstract description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 8
- 235000019425 dextrin Nutrition 0.000 claims abstract description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 8
- 239000008213 purified water Substances 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- YZNWXXJZEDHRKB-UHFFFAOYSA-N octadecyl 2-hydroxypropanoate;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCCOC(=O)C(C)O YZNWXXJZEDHRKB-UHFFFAOYSA-N 0.000 claims abstract description 3
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000002156 mixing Methods 0.000 claims description 42
- 239000000243 solution Substances 0.000 claims description 36
- 239000011259 mixed solution Substances 0.000 claims description 24
- 210000000265 leukocyte Anatomy 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 238000009835 boiling Methods 0.000 claims description 12
- 238000007865 diluting Methods 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- YFBRYDITTBYWAL-KTKRTIGZSA-N 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOCCOCCOCCO YFBRYDITTBYWAL-KTKRTIGZSA-N 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 7
- 238000002791 soaking Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000013011 aqueous formulation Substances 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供一种缓解术后白细胞升高的中药配方及其制备工艺,配方中各组份按质量百分比计,包括:按质量百分比计,包括:人参33%‑40%;黄精50%‑53%;增稠剂6%‑8%;润湿剂6%‑8%,其中,所述的润湿剂为硬脂酰乳酸钠(SSL)、司盘20(Span20)、四乙二醇单油酸酯(Atlas G2140)中的至少一种;所述的增稠剂为黄原胶、羧甲基纤维素钠、抗性糊精中的至少一种。本发明还提供了利用纯化水(0.1‑1.0μm)制备汤剂的工艺,采用本发明方法制备的水溶液可长期保存,稳定性表现良好,可用于缓解术后白细胞升高。
Description
技术领域
本发明涉及一种缓解术后白细胞升高的中药配方及其制备工艺,属于药食同源领域。
背景技术
人体内白细胞总数和种类是相对稳定的。白细胞分为中性粒细胞、嗜酸性粒细胞、嗜碱性粒细胞、单核细胞、淋巴细胞。白细胞是人体与疾病斗争的"卫士"。当病菌侵入人体体内时,白细胞能通过变形而穿过毛细血管壁,集中到病菌入侵部位,将病菌包围﹑吞噬。如果体内的白细胞的数量高于正常值,很可能是身体有了炎症。正常人白细胞总数在(4.0~10.0)×10^9/L。高于10.0×10^9/L通常被认为是异常,白细胞数量增多常见于急性细菌性感染、严重组织损伤、大出血、中毒和白血病等。
人参,具有大补元气,补脾益肺,生津,安神益智的功效。主治气虚欲脱,脉微欲绝,脾气不足,中气下陷,肺虚喘咳,气短乏力,津伤口渴,虚热消渴,失眠健忘,心悸怔忡,血虚萎黄,阳痿、宫冷等。黄精,具有养阴润肺,补脾益气,滋肾填精的功效。主治阴虚、劳嗽,肺燥咳嗷,脾虚乏力,食少口干,消渴;肾亏腰膝酸软,耳鸣目暗,须发早白,体虚羸瘦,风癞癣疾。本专利涉及到制备缓解术后白细胞升高的中药配方。
发明内容
本发明目的在于提供一种缓解术后白细胞升高的中药配方。
本发明的再一目的在于:提供一种上述缓解术后白细胞升高的中药配方的制备工艺。
本发明目的提供以下方案实现:一种缓解术后白细胞升高的中药配方,按质量百分比计:人参33%-40%;黄精50%-53%;增稠剂 6%-8%;润湿剂 6%-8%,其中,所述的润湿剂为硬脂酰乳酸钠(SSL)、司盘20(Span20)、四乙二醇单油酸酯(Atlas G2140)中的至少一种;所述的增稠剂为黄原胶、羧甲基纤维素钠、抗性糊精中的至少一种。
本发明还提供了一种缓解术后白细胞升高的中药配方的汤剂的制备工艺,包括以下步骤:
(1)按质量百分比将人参、黄精进行混合,加入2倍量纯水浸泡30分钟;武火煮沸后转为中火,继续煎煮30分钟;倒出煎液,再加水煎煮20分钟,最后将两次煎煮液合并;
(2)润湿剂加入到纯水中进行溶解混匀,调整HLB(Hydrophile-LipophileBalance Number,亲水疏水平衡值)值 7-9,得到润湿剂溶液;
(3)将步骤(2)制备的润湿剂溶液与步骤(1)制备的煎煮液进行混匀,得混合溶液;
(4)将增稠剂溶解于步骤(3)制备的混合溶液中,加纯化水至550-650ml,分装、灭菌。
采用本发明方法得到的汤剂可长期保存,稳定性表现良好。可以用于缓解术后白细胞升高。
具体实施方式
实施例1
一种缓解术后白细胞升高的中药配方:
人参:10g
黄精:15g
SSL (润湿剂):2g
黄原胶(增稠剂):2g
纯化水:1000ml。
制备工艺:
(1)取配方中人参10g、黄精15g混合,加入2倍量纯化水(0.1-1.0μm)浸泡30分钟;武火煮沸后转为中火,继续煎煮30分钟;倒出煎液,再加水煎煮20分钟,最后将两次煎煮液合并;
(2)取配方SSL 2g,加入10-30ml纯水中混合均匀,调整HLB值7-9,得到SSL溶液备用;
(3)将步骤(2)制备的SSL溶液与步骤(1)制备的溶液进行混匀,得到混合溶液;
(4)将黄原胶1.8-2.2g溶解于步骤(3)制备的混合溶液中,加水至550-650ml,分装、灭菌,得到灭菌缓解术后白细胞升高的中药汤剂。
实施例2
润湿剂选择:
实验配方中,其他与实施例1保持一致,只是润湿剂分别选SSL、司盘20(Span20)、四乙二醇单油酸酯(Atlas G2140)进行试验,观察其稳定性。
实验步骤:
1、润湿剂选SSL:
(1)取配方中人参、黄精混合,加入2倍量纯水浸泡30分钟,武火煮沸后转为中火,继续煎煮30分钟;倒出煎液,再加水煎煮20分钟后,将两次煎煮液合并;
(2)取SSL 1.8-2.2g,加入10-30ml纯水中,调整HLB值7-9得SSL溶液备用;
(3)在步骤(1)得到的煎煮液中加入SSL溶液进行混匀,得混合溶液;
(4)黄原胶1.8-2.2g加入到步骤(3)所得的混合溶液中,纯水稀释至550-650ml,混匀、分装,灭菌,即配方水溶液-1。
该水溶液-1在室温静置1周,目测溶液稳定性状态是否有“相变”过程,如溶液变胶体,澄清变混浊等现象,如有,则视为不稳定,实现结果见表1,稳定。
2、润湿剂选取Span20:
(1)取配方中人参、黄精混合,加入2倍量纯水浸泡30分钟,武火煮沸后转为中火,继续煎煮30分钟;倒出煎液,再加水煎煮20分钟后,将两次煎煮液合并;
(2)取Span20 1.8-2.2g,加入10-30ml纯水中,调整HLB值7-9得Span20溶液备用;
(3)将Span20溶液加入步骤(1)的煎煮液中进行混匀,得混合溶液;
(4)在步骤(3)所得混合溶液中加入黄原胶1.8-2.2g进行溶解混匀,纯水稀释至550-650ml,混匀、分装,灭菌,即配方水溶液-2。
该水溶液-2在室温静置1周,目测溶液稳定性状态是否有“相变”过程,如溶液变胶体,澄清变混浊等现象,如有,则视为不稳定,实现结果见表1,较稳定。
3、润湿剂选取Atlas G2140:
(1)取配方中人参、黄精混合,加入2倍量纯水浸泡30分钟,武火煮沸后转为中火,继续煎煮30分钟;倒出煎液,再加水煎煮20分钟后,将两次煎煮液合并;
(2)取配方Atlas G2140 1.8-2.2g,加入10-30ml纯水中,调整HLB值7-9得AtlasG2140备用;
(3)在步骤(1)的煎煮液中加入Atlas G2140溶液进行混匀,得混合溶液;
(4)在步骤(3)的混合溶液中加入黄原胶1.8-2.2g进行溶解混匀,纯水稀释至550-650ml,混匀、分装,灭菌,即配方水溶液-3。
该水溶液-3在室温静置1周,目测溶液稳定性状态是否有“相变”过程,如溶液变胶体,澄清变混浊等现象,如有,则视为不稳定,实现结果见表1,较稳定。
表1,配方水溶液静置1周的稳定性
项目 | 配方水溶液-1 | 配方水溶液-2 | 配方水溶液-3 |
乳化剂 | SSL | Span20 | Atlas G2140 |
稳定性 | 稳定 | 较稳定 | 较稳定 |
实施例3
增稠剂选择
实验配方中,其他与实施例1保持一致,只是增稠剂分别选用黄原胶、羧甲基纤维素钠、抗性糊精进行试验,观察粘稠度。
1、增稠剂选用黄原胶:
(1)取配方中人参、黄精混合,加入2倍量纯水浸泡30分钟,武火煮沸后转为中火,继续煎煮30分钟;倒出煎液,再加水煎煮20分钟后,将两次煎煮液合并;
(2)取SSL 1.8-2.2g,加入10-30ml纯水中,调整HLB值7-9得SSL溶液备用;
(3)在步骤(1)煎煮液中加入SSL溶液进行混匀,得混合溶液;
(4)在步骤(3)混合溶液中加入黄原胶1.8-2.2g进行溶解混匀,纯水稀释至550-650ml,混匀、分装,灭菌,即配方水溶液-4。
目测水溶液-4稳定性是否良好,如呈澄清透明状,且静置7天未见相变现象,则稳定性良好;另外静置7天后,观察其软化性,若7天以后呈固态,无法搅拌或称量,则视流变性不好,或粘性大;若仍呈液体状态,方便滴管等容器量取,则视为流变性良好,实验结果见表2,稳定且流变性好。
2、增稠剂选用羧甲基纤维素钠:
(1)取配方中人参、黄精混合,加入2倍量纯水浸泡30分钟,武火煮沸后转为中火,继续煎煮30分钟;倒出煎液,再加水煎煮20分钟后,将两次煎煮液合并;
(2)取SSL 1.8-2.2g,加入10-30ml纯水中,调整HLB值7-9得SSL溶液备用;
(3)在步骤(1)的煎煮液中加入SSL溶液进行混匀,得混合溶液;
(4)在步骤(3)的混合溶液中加入羧甲基纤维素钠1.8-2.2g进行溶解混匀,纯水稀释至550-650ml,混匀、分装,灭菌,即配方水溶液-5。
目测水溶液-5稳定性是否良好,如呈澄清透明状,且静置7天未见相变现象,则稳定性良好;另外静置7天后,观察其软化性,若7天以后呈固态,无法搅拌或称量,则视流变性不好,或粘性大;若仍呈液体状态,方便滴管等容器量取,则视为流变性良好,实验结果见表2,稳定且流变性良好。
3、增稠剂选用抗性糊精:
(1)取配方中人参、黄精混合,加入2倍量纯水浸泡30分钟,武火煮沸后转为中火,继续煎煮30分钟;倒出煎液,再加水煎煮20分钟后,将两次煎煮液合并;
(2)取SSL 1.8-2.2g,加入10-30ml纯水中,调整HLB值7-9得SSL溶液备用;
(3)在步骤(1)的煎煮液中加入SSL溶液进行混匀,得混合溶液;
(4)在步骤(3)的混合溶液中加入抗性糊精1.8-2.2g进行溶解混匀,纯水稀释至550-650ml,混匀、分装,灭菌,即配方水溶液-6。
目测水溶液-6稳定性是否良好,如呈澄清透明状,且静置7天未见相变现象,则稳定性良好;另外静置7天,观察其软化性,若7天以后呈固态,无法搅拌或称量,则视流变性不好,或粘性大;若仍呈液体状态,方便滴管等容器量取,则视为流变性良好,实验结果见表2,稳定且流变性良好。
表2增稠剂对汤剂稳定性和流变性的影响
配方水溶液-4 | 配方水溶液-5 | 配方水溶液-6 | |
增稠剂 | 黄原胶 | 羧甲基纤维素钠 | 抗性糊精 |
稳定性 | 稳定 | 稳定 | 稳定 |
流变性 | 好 | 良好 | 良好 |
实施例4
一种缓解术后白细胞升高的中药配方:
人参:15g
黄精:23g
SSL (润湿剂):3g
黄原胶(增稠剂):3g
纯化水:1000ml
制备工艺:
(1)取配方中人参15g、黄精23g混合,加入2倍量纯水浸泡30分钟,武火煮沸后转为中火,继续煎煮30分钟;倒出煎液,再加水煎煮20分钟后,将两次煎煮液合并;
(2)取SSL 2.8~3.2g,加入10-30ml纯水中,调整HLB值7-9得SSL溶液备用;
(3)在步骤(1)的煎煮液中加入SSL溶液进行混匀,得混合溶液;
(4)在步骤(3)的混合溶液中加入黄原胶2.8~3.2g进行溶解混匀,纯水稀释至550-650ml,混匀、分装,灭菌,得到缓解术后白细胞升高的中药汤剂。
应用例
案例1. 赖某,女,1979年生
患者术后生白细胞数升高,检测值为14(正常范围3.5~9.5),单核细胞、中心粒细胞等均升高。采用本发明方剂,服用2周,每日2次。患者2周后血象恢复正常。
综上所述,本发明配方水溶液可长期保存,稳定性表现良好。所得配方水溶液可用于缓解术后白细胞升高。以上所述仅为本发明的较佳实施案例而已,并不用以限制本发明,凡在本发明的原则内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (6)
1.一种缓解术后白细胞升高的中药配方,其特征在于,按质量百分比计,包括:人参33%-40%;黄精50%-53%;增稠剂 6%-8%;润湿剂 6%-8%,其中,所述的润湿剂为硬脂酰乳酸钠(SSL)、司盘20(Span20)、四乙二醇单油酸酯(Atlas G2140)中的至少一种;所述的增稠剂为黄原胶、羧甲基纤维素钠、抗性糊精中的至少一种。
2.一种根据权利要求1所述的缓解术后白细胞升高的中药配方的汤剂制备工艺,其特征在于,包括以下步骤:
(1)按质量百分比将人参、黄精进行混合,加入2倍量纯水浸泡30分钟;武火煮沸后转为中火,继续煎煮30分钟;倒出煎液,再加水煎煮20分钟,最后将两次煎煮液合并;
(2)润湿剂加入到纯水中进行溶解混匀,调整HLB值 7-9,得到润湿剂溶液;
(3)将步骤(2)制备的润湿剂溶液与步骤(1)制备的煎煮液进行混匀,得混合溶液;
(4)将增稠剂溶解于步骤(3)制备的混合溶液中,加纯化水至550-650ml,分装、灭菌。
3.根据权利要求2所述的缓解术后白细胞升高的中药配方的汤剂制备工艺,其特征在于,按下述步骤制备:
(1)取配方中人参10g、黄精15g混合,加入2倍量纯水浸泡30分钟;武火煮沸后转为中火,继续煎煮30分钟;倒出煎液,再加水煎煮20分钟后,将两次煎煮液合并;
(2)取配方润湿剂 1.8-2.2g,加入10-30ml纯水中混合均匀,调整HLB值7-9,得到润湿剂溶液备用;
(3)将步骤(2)制备的润湿剂溶液与步骤(1)制备的煎煮液进行混匀,得到混合溶液;
(4)将增稠剂1.8-2.2g溶解于步骤(3)制备的混合溶液中,加水至550-650ml,分装、灭菌,得到灭菌缓解术后白细胞升高的中药汤剂。
4.根据权利要求3所述的缓解术后白细胞升高的中药配方的汤剂制备工艺,其特征在于,所述的润湿剂分别选SSL、司盘20(Span20)或四乙二醇单油酸酯(Atlas G2140);所述的增稠剂为黄原胶。
5.根据权利要求3所述的缓解术后白细胞升高的中药配方的汤剂制备工艺,其特征在于,按下述步骤制备:
所述的润湿剂选用SSL;、司盘20(Span20)或四乙二醇单油酸酯(Atlas G2140);所述的增稠剂分别选黄原胶、羧甲基纤维素钠或抗性糊精。
6.根据权利要求2所述的缓解术后白细胞升高的中药配方的汤剂制备工艺,其特征在于,按下述步骤制备:
(1)取配方中人参15g、黄精23g混合,加入2倍量纯水浸泡30分钟,武火煮沸后转为中火,继续煎煮30分钟;倒出煎液,再加水煎煮20分钟后,将两次煎煮液合并;
(2)取SSL 2.8~3.2g,加入10-30ml纯水中,调整HLB值7-9得SSL溶液备用;
(3)在步骤(1)的煎煮液中加入SSL溶液进行混匀,得混合溶液;
(4)在步骤(3)的混合溶液中加入黄原胶2.8~3.2g进行溶解混匀,纯水稀释至550-650ml,混匀、分装,灭菌,得到缓解术后白细胞升高的中药汤剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210146859.8A CN114470096A (zh) | 2022-02-17 | 2022-02-17 | 一种缓解术后白细胞升高的中药配方及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210146859.8A CN114470096A (zh) | 2022-02-17 | 2022-02-17 | 一种缓解术后白细胞升高的中药配方及其制备工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114470096A true CN114470096A (zh) | 2022-05-13 |
Family
ID=81481717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210146859.8A Pending CN114470096A (zh) | 2022-02-17 | 2022-02-17 | 一种缓解术后白细胞升高的中药配方及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114470096A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1189309A (zh) * | 1998-02-16 | 1998-08-05 | 王和建 | 参鸡黄精汤 |
CN106615549A (zh) * | 2016-11-17 | 2017-05-10 | 安徽省旌德博仕达农业科技有限公司 | 一种人参黄精含片及其制备方法 |
-
2022
- 2022-02-17 CN CN202210146859.8A patent/CN114470096A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1189309A (zh) * | 1998-02-16 | 1998-08-05 | 王和建 | 参鸡黄精汤 |
CN106615549A (zh) * | 2016-11-17 | 2017-05-10 | 安徽省旌德博仕达农业科技有限公司 | 一种人参黄精含片及其制备方法 |
Non-Patent Citations (1)
Title |
---|
谢宇等: "《活学活用神农本草经》", 31 August 2018, 湖北科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102525871B (zh) | 用于预防和治疗复发性口疮的牙膏及制备方法 | |
CN102742691A (zh) | 具有降血压作用的保健茶饮品及制备方法 | |
CN113713052A (zh) | 一种眼球明眸调理营养液膏及其制备方法 | |
CN109674875A (zh) | 口腔溃疡护理精华液 | |
CN114470096A (zh) | 一种缓解术后白细胞升高的中药配方及其制备工艺 | |
CN106727026B (zh) | 一种中药祛痘组合物及其应用 | |
CN114452360B (zh) | 一种小雨燕窝修护滋养凝胶及制备方法 | |
CN106727112A (zh) | 一种天然抗敏组合物及其制备方法和应用 | |
CN102940867A (zh) | 一种治疗干眼症的中药组合物 | |
CN106038334A (zh) | 含有苦丁茶提取物的抑菌祛味牙膏 | |
CN105560891A (zh) | 一种含有冰片的中药滴眼剂及其制备方法 | |
CN103372087A (zh) | 一种护肤保健的中药组合物 | |
LU102388B1 (en) | Silver ion bacteriostatic hand sanitizer and preparation method and application thereof | |
CN113797252A (zh) | 一种解酒毒的配方及其制备工艺 | |
WO2019104931A1 (zh) | 一种治疗白血病的中药组合物及其制备方法 | |
CN112089792A (zh) | 一种净颜膏及其制备方法 | |
CN105943718B (zh) | 一种沉香复方中药组合物及其制备方法、应用 | |
CN113797281A (zh) | 一种改善肥胖的配方及其制备工艺 | |
CN112472772A (zh) | 一种抑菌凝胶及其制备方法 | |
CN104383314A (zh) | 用于治疗流行性角膜炎的药物 | |
CN111329972A (zh) | 一种复方暖宫止痛足浴泡腾片及其制备方法 | |
CN112336838A (zh) | 治疗干眼症的中药组方眼药水及其制备方法 | |
CN110721285A (zh) | 一种用于补元气安心神健脾祛湿调节机体免疫力的中药组合物及其制备方法 | |
CN108452154A (zh) | 改善风湿性关节炎的中药泡浴速溶颗粒及制备与使用方法 | |
CN111956741B (zh) | 一种促进唾液分泌、减轻口腔干燥的植物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220513 |